SG11201806372UA - Nucleic acid conjugate - Google Patents

Nucleic acid conjugate

Info

Publication number
SG11201806372UA
SG11201806372UA SG11201806372UA SG11201806372UA SG11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA
Authority
SG
Singapore
Prior art keywords
nucleic acid
acid conjugate
independently
formula
oligonucleotide
Prior art date
Application number
SG11201806372UA
Other languages
English (en)
Inventor
Keiji Uehara
Yasuhiro Suzuki
Hiroto Iwai
Masakazu Homma
Yuichi Fukuda
Tatsuto Kiuchi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of SG11201806372UA publication Critical patent/SG11201806372UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201806372UA 2016-01-29 2017-01-30 Nucleic acid conjugate SG11201806372UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016016707 2016-01-29
PCT/JP2017/003249 WO2017131236A1 (ja) 2016-01-29 2017-01-30 核酸複合体

Publications (1)

Publication Number Publication Date
SG11201806372UA true SG11201806372UA (en) 2018-08-30

Family

ID=59398306

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806372UA SG11201806372UA (en) 2016-01-29 2017-01-30 Nucleic acid conjugate

Country Status (11)

Country Link
US (1) US10745700B2 (ja)
EP (1) EP3409780B1 (ja)
JP (1) JP6853193B2 (ja)
KR (1) KR20180103166A (ja)
CN (1) CN108699558B (ja)
AU (1) AU2017213404A1 (ja)
CA (1) CA3012967A1 (ja)
ES (1) ES2858090T3 (ja)
SG (1) SG11201806372UA (ja)
TW (1) TWI733751B (ja)
WO (1) WO2017131236A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952757T3 (es) * 2016-06-30 2023-11-03 Kyowa Kirin Co Ltd Complejo de ácidos nucleicos
US11963974B2 (en) 2017-03-10 2024-04-23 National Center For Child Health And Development Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
JPWO2018199340A1 (ja) 2017-04-28 2020-03-12 協和キリン株式会社 オリゴヌクレオチド誘導体またはその塩
TW201920668A (zh) * 2017-08-02 2019-06-01 日商協和醱酵麒麟有限公司 核酸複合體
TW201909925A (zh) * 2017-08-02 2019-03-16 日商協和醱酵麒麟有限公司 核酸複合體
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US11958878B2 (en) 2018-03-09 2024-04-16 Daiichi Sankyo Company, Limited Therapeutic agent for glycogen storage disease type IA
WO2019243391A1 (en) * 2018-06-21 2019-12-26 F. Hoffmann-La Roche Ag Hybridizing all-lna oligonucleotides
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) * 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド siRNA複合体及びその調製方法と使用
EP3873486A4 (en) * 2018-11-02 2022-10-19 Arbutus Biopharma Corporation BIVALENT TARGETED CONJUGATES
US20220127605A1 (en) * 2018-11-30 2022-04-28 Kyowa Kirin Co., Ltd. Nucleic acid conjugate
JPWO2021049504A1 (ja) 2019-09-10 2021-03-18
CA3150890A1 (en) * 2019-09-17 2021-03-25 Philip Stewart Low Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
WO2023143374A1 (zh) * 2022-01-30 2023-08-03 成都凌泰氪生物技术有限公司 一种配体、其制备方法及应用
WO2023187760A1 (en) * 2022-04-01 2023-10-05 Genevant Sciences Gmbh Mannose-targeted compositions
CN116444589B (zh) * 2023-06-15 2023-09-19 北京悦康科创医药科技股份有限公司 新型GalNAc化合物及其硫代寡核苷酸缀合物和偶联方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
ATE227342T1 (de) 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
AU1039397A (en) * 1995-11-22 1997-06-27 Johns Hopkins University, The Ligands to enhance cellular uptake of biomolecules
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US20080199960A1 (en) 2004-05-13 2008-08-21 Juliano Rudolph L Methods for the Delivery of Oligomeric Compounds
EP4223299A3 (en) 2007-12-04 2023-08-30 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
ES2370638B1 (es) 2010-03-05 2012-11-16 Universidad De Castilla La Mancha Dendrimeros como vehiculos no virales para terapia genica
AU2011343664B2 (en) * 2010-12-17 2015-10-08 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
CN103649311A (zh) * 2011-06-03 2014-03-19 国立大学法人北海道大学 寡核苷酸衍生物、包含寡核苷酸衍生物的治疗用医药组合物及诊断用医药组合物、以及miRNA机能抑制用寡核苷酸衍生物
SG10201912170WA (en) 2011-11-18 2020-02-27 Alnylam Pharmaceuticals Inc Rnai Agents, Compositions And Methods Of Use Thereof For Treating Transthyretin (TTR) Associated Diseases
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
TWI595885B (zh) 2012-05-02 2017-08-21 喜納製藥公司 包含四galnac之新穎結合物及傳送寡核苷酸之方法
CA2873772A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating bdnf expression
JP2016522674A (ja) 2012-05-16 2016-08-04 ラナ セラピューティクス インコーポレイテッド 遺伝子発現を調節するための組成物及び方法
KR20150083920A (ko) * 2012-11-15 2015-07-20 로슈 이노베이션 센터 코펜하겐 에이/에스 항 apob 안티센스 접합체 화합물
AU2014259750B2 (en) 2013-05-01 2019-02-28 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
AU2014287002A1 (en) 2013-07-11 2016-02-11 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
JP6482475B2 (ja) 2014-01-07 2019-03-13 レナセラピューティクス株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
ES2952757T3 (es) * 2016-06-30 2023-11-03 Kyowa Kirin Co Ltd Complejo de ácidos nucleicos

Also Published As

Publication number Publication date
ES2858090T3 (es) 2021-09-29
JP6853193B2 (ja) 2021-03-31
CA3012967A1 (en) 2017-08-03
AU2017213404A1 (en) 2018-09-20
CN108699558A (zh) 2018-10-23
US20190055558A1 (en) 2019-02-21
US10745700B2 (en) 2020-08-18
JPWO2017131236A1 (ja) 2018-11-22
EP3409780A1 (en) 2018-12-05
TWI733751B (zh) 2021-07-21
EP3409780B1 (en) 2021-01-20
TW201730200A (zh) 2017-09-01
WO2017131236A1 (ja) 2017-08-03
CN108699558B (zh) 2021-12-07
EP3409780A4 (en) 2019-09-25
KR20180103166A (ko) 2018-09-18

Similar Documents

Publication Publication Date Title
SG11201806372UA (en) Nucleic acid conjugate
NZ630800A (en) Methods of preparing substituted nucleotide analogs
WO2015073575A3 (en) Residualizing linkers and uses thereof
PH12020550132A1 (en) Novel enantiomers of a series of antiviral compounds
IN2015DN01061A (ja)
PH12018501642B1 (en) Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof
AU2018301662A1 (en) Purified 2,5-furandicarboxylic acid pathway products
CA3010551A1 (en) Pyrrolobenzodiazepine conjugates
WO2014207567A3 (en) Process for the preparation of abiraterone and intermediates thereof
WO2016099727A3 (en) Ligand components, associated reaction products, activated reaction products, hydrosilylation catalysts and hydrosilylation curable compositions including the ligand components, and associated methods for preparing same
MX2016002217A (es) Compuestos con actividad pesticida.
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
WO2017035319A8 (en) Methods for treatment of polycystic kidney disease
MX350430B (es) Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico.
WO2013121279A3 (en) Process to prepare ertapenem
WO2015111004A3 (en) Improved process for the preparation of chlorophenyl trifluoroethanone
WO2014097272A3 (en) Process for the preparation of (s,s)-6-benzloctahydro-1 h-pyrrolo[3,4-b]pyridine,an intermediate of azabicyclopyridine derivatives
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MY186779A (en) Nucleic acid derivative having immunostimulatory activity
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
WO2017046816A3 (en) Process for the preparation of derivatives of benzodioxole
WO2017004172A8 (en) Total synthesis of shishijimicin a and analogs thereof
IN2015DN02699A (ja)
WO2016005474A8 (en) Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein
GB201912021D0 (en) Methods, products & Uses relating thereto